Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)

Common Bile Duct Stones Clinical Trial

Official title:

Clinical Feasibility and Efficacy of a New Digital Single-operator Peroral Cholangiopancreatioscopy System: a Multicenter Registry

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02776709
• Other study ID #: STU00201104
• Status: Withdrawn
• Start date: July 2015
• Est. completion date: May 2018

Study information

• Verified date: December 2020
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Cholangioscopy, or direct visualization of the bile ducts was first documented in the late 1970s and has made many advances over the last few decades. The advent of mother-baby scopes allowed for both diagnostic and therapeutic procedures, though the early scopes were often fragile, and cumbersome due to the need for two endoscopists. Ultraslim endoscopes later became popular as a method to digitally view the bile ducts, however, often needed guide-wire or balloon-assistance to allow for cannulation. Other disadvantages of these systems included limited steerability, and poor irrigation capabilities.

The advent of Spyglass, a single-operator peroral cholangioscopy method allowed for a fiberoptic, catheter-based system that could be easily used for diagnostic and therapeutic purposes in the biliary system. However, image quality was often lacking due to the fiberoptic technology. The new digital Spyglass system rectifies this inadequacy by introducing a digital sensor for better image quality, which will allow for better visualization and diagnosis of indeterminate strictures. Furthermore, modification of the scope platform allows for efficient use, reliable directionality of the scope tip, and improved ease of passage of accessories during therapeutic procedures such clearing stones or stent placement.

Description:

All patients referred for the evaluation of indeterminate strictures or removal of difficult stones will be eligible for enrollment in the consortium. The PI or study coordinator will meet with the patient and discuss the study, its objectives, and obligations with each patient. After full disclosure, informed consent will be obtained.

Upon consent, basic demographics and data from prior procedures (when available) will be recorded. An endoscopist proficient in ERCP, with expertise in cholangioscopy, will perform the procedures using the Spyglass DS system with its associated components including biopsy forceps (SpyBiteTM) and other accessories as necessary. Procedure time, visual findings, number of biopsies taken, pathology, stone location, stone size, and method of stone clearance and adverse events will be recorded on data collection forms and transferred into a centralized password protected database. All patients will be followed for 6-12 months or surgery (stricture cohort) to assess accuracy or stone recurrence rates.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All patients referred for the evaluation of indeterminate strictures or removal of difficult stones.

Exclusion Criteria:

• All patients who are unable or unwilling to give consent will not be included in this study

Related Conditions & MeSH terms

• Bile Duct Strictures
• Common Bile Duct Stones
• Constriction, Pathologic

Intervention

Procedure:
• ERCP with cholangioscopy

Locations

Country	Name	City	State
United States	University of Colorado, Denver	Denver	Colorado
United States	UCLA Medical Center	Los Angeles	California
United States	Ochsner Medical Center	New Orleans	Louisiana
United States	University of Utah	Salt Lake City	Utah
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (6)

Lead Sponsor	Collaborator
Northwestern University	H. Lee Moffitt Cancer Center and Research Institute, Ochsner Health System, University of California, Los Angeles, University of Colorado, Denver, University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stone clearance rate	% of complete removal of bile duct stones	6 months
Secondary	Diagnostic accuracy for indeterminate bile duct strictures	Correlation of pathology with surgical specimen or 6month f/u	6 months